dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Casarrubios García, Marta |
dc.contributor.author | Cruz-Bermúdez, Alberto |
dc.contributor.author | Martínez Marti, Alexandre |
dc.contributor.author | Martínez Marti, Alexandre |
dc.contributor.author | Insa, Amelia |
dc.contributor.author | Nadal, Ernest |
dc.contributor.author | Lázaro, Martín |
dc.contributor.author | Garcia Campelo, Rosario |
dc.date.accessioned | 2022-06-13T09:57:37Z |
dc.date.available | 2022-06-13T09:57:37Z |
dc.date.issued | 2021-11-01 |
dc.identifier.citation | Casarrubios M, Cruz-Bermúdez A, Nadal E, Insa A, del Rosario García Campelo M, Lázaro M, et al. Pretreatment tissue TCR repertoire evenness is associated with complete pathologic response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy. Clin Cancer Res. 2021 Nov 1;27(21):5878–90. |
dc.identifier.issn | 1557-3265 |
dc.identifier.uri | https://hdl.handle.net/11351/7664 |
dc.description | Quimioimmunoteràpia neoadjuvant; Càncer de pulmó; Receptor de cèl·lules T |
dc.language.iso | eng |
dc.publisher | American Association for Cancer Research |
dc.relation.ispartofseries | Clinical Cancer Research;27(21) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Pulmons - Càncer - Tractament |
dc.subject | Cèl·lules T - Receptors |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject.mesh | Carcinoma, Non-Small-Cell Lung |
dc.subject.mesh | /therapy |
dc.subject.mesh | Receptors, Antigen, T-Cell |
dc.title | Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1158/1078-0432.CCR-21-1200 |
dc.subject.decs | carcinoma de pulmón de células no pequeñas |
dc.subject.decs | /terapia |
dc.subject.decs | receptores de antígenos de linfocitos T |
dc.relation.publishversion | https://doi.org/10.1158/1078-0432.CCR-21-1200 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Casarrubios M, Cruz-Bermúdez A] Servicio de Oncología Médica, Instituto de Investigacion Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain. [Nadal E] Institut Català d’Oncologia, L’Hospitalet de Llobregat, L’Hospitalet De Llobregat, Barcelona, Spain. [Insa A] Fundacion INCLIVA, Hospital Clínico Universitario de Valencia, Valencia, Spain. [García Campelo MDR] Hospital Universitario A Coruna, A Coruña, Spain. [Lázaro M] Hospital Universitario de Vigo, Pontevedra, Spain. [Martínez-Martí A] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 34376534 |
dc.identifier.wos | 000714656500019 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |